Ryvu Therapeutics S.A. (WSE:RVU)

Ryvu Therapeutics Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	160.07	57.94	101.92	83.24	136.22
Short-Term Investments	65.86	175.73	0.53	4.99	24.97
Cash & Short-Term Investments	225.93	233.67	102.45	88.23	161.19
Cash Growth	-3.31%	128.09%	16.11%	-45.26%	123.54%
Accounts Receivable	15.66	9.19	1.05	5.94	2.2
Other Receivables	10.92	23.65	258.85	5.8	5.75
Receivables	26.58	32.84	259.89	11.74	7.95
Inventory	1.21	2.12	1.76	1.96	1.68
Prepaid Expenses	-	-	2.35	1.63	0.58
Other Current Assets	18.72	9.77	1.48	0.69	0.98
Total Current Assets	272.44	278.39	367.93	104.25	172.36
Property, Plant & Equipment	72.74	77.56	82.22	91.18	91.16
Long-Term Investments	16.77	34.37	20.48	29.4	29.12
Other Intangible Assets	8.12	6.34	4.28	3.04	2.32
Long-Term Deferred Tax Assets	-	-	-	0.33	0.59
Other Long-Term Assets	8.72	6.55	0.08	0.6	0.09
Total Assets	378.78	403.2	474.98	228.81	295.64
Accounts Payable	31.15	23.14	12.58	11.69	6.26
Accrued Expenses	12.28	12.22	11.7	4.86	5.31
Short-Term Debt	0.29	0.13	0.06	0.02	0
Current Portion of Long-Term Debt	25.79	-	0.81	0.81	0.81
Current Portion of Leases	0.5	0.41	1.03	1.92	2.27
Current Income Taxes Payable	-	-	-	5.46	-
Current Unearned Revenue	35.71	31.53	16.71	8.95	14.56
Other Current Liabilities	2.21	2.27	1.93	2.5	4.6
Total Current Liabilities	107.93	69.7	44.81	36.2	33.81
Long-Term Debt	82.56	8.85	9.9	8.86	1.55
Long-Term Leases	1.39	0.37	0.87	1.58	2.77
Long-Term Unearned Revenue	42.74	64.26	75.8	20.26	27.5
Long-Term Deferred Tax Liabilities	-	-	-	0.44	6.04
Other Long-Term Liabilities	-	-	0.06	0.06	-
Total Liabilities	234.89	143.61	131.59	67.51	71.92
Common Stock	9.25	9.25	7.34	7.34	7.34
Additional Paid-In Capital	519.75	519.75	279.06	279.06	279.06
Retained Earnings	-111.44	-0.01	92.1	175.88	261.54
Comprehensive Income & Other	-273.67	-269.39	-35.12	-300.99	-324.22
Total Common Equity	143.88	259.59	343.39	161.3	223.72
Shareholders' Equity	143.88	259.59	343.39	161.3	223.72
Total Liabilities & Equity	378.78	403.2	474.98	228.81	295.64
Total Debt	110.53	9.76	12.67	13.19	7.41
Net Cash (Debt)	115.4	223.91	89.77	75.04	153.78
Net Cash Growth	-48.46%	149.42%	19.63%	-51.20%	144.52%
Net Cash Per Share	4.99	9.78	4.89	4.09	9.17
Filing Date Shares Outstanding	23.12	23.12	23.12	18.36	18.36
Total Common Shares Outstanding	23.12	23.12	23.12	18.36	18.36
Working Capital	164.51	208.69	323.12	68.05	138.55
Book Value Per Share	6.22	11.23	14.85	8.79	12.19
Tangible Book Value	135.77	253.26	339.11	158.26	221.4
Tangible Book Value Per Share	5.87	10.95	14.67	8.62	12.06
Land	7.47	7.47	7.47	7.47	7.47
Buildings	52.21	52.2	52.15	53	48.33
Machinery	16.09	15.38	14.15	13.8	13.11
Construction In Progress	0.35	-	-	0.61	4.58

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.